Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change fro

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Bu

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

The V012 clinical study is designed to demonstrate the efficacy and safety of the ATEV as a dialysis

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Humacyte (NASDAQ:HUMA) with a B

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consens

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universa

Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Sm